John Schmid serves as a member of the boards of directors of AnaptysBio, Inc. (ANAB), Helix Acquisition Corp II (HLXB), and Xeris Pharmaceuticals (XERS). In addition, Mr. Schmid serves as chairman of the board of directors of Speak, Inc., a speakers bureau, which he helped found in 1989. Mr. Schmid also served as a member of the boards of directors of Poseida Therapeutics Inc., Neos Therapeutics, Blacksmith Medicines (formerly known as Forge Therapeutics, Inc.) and Helix Acquisition Corporation. Previously, Mr. Schmid served as chief financial officer of Auspex Pharmaceuticals, Inc. until its sale to Teva Pharmaceutical Industries Ltd. Prior to that, Mr. Schmid co-founded Trius Therapeutics where he served as the chief financial officer until its merger with Cubist Pharmaceuticals, Inc. Prior to Trius Therapeutics, Mr. Schmid served as the chief financial officer of GeneFormatics, Inc. and Endonetics Inc. Mr. Schmid received a B.A. in Economics from Wesleyan University and an M.B.A. from the University of San Diego.